BioClinica Names David Peters New Chief Financial Officer

NEWTOWN, Pa., June 2, 2015 /PRNewswire/ -- BioClinica^®, Inc., a specialty clinical trials services and technology provider, today announced that David Peters, an accomplished senior finance and accounting executive, has been named Executive Vice President and Chief Financial Officer (CFO) and will be joining BioClinica on June 8, 2015.

Peters brings more than 25 years of financial and accounting experience with a focus in pharmaceutical services. "David has extensive and deep knowledge in all areas of finance, accounting and business operations and understands the specifics of our high growth and diverse business segments in both private and public markets, making him well-suited for the position," said BioClinica CE0 John Hubbard, Ph.D.

Peters has directed all facets of accounting, financial functions and strategy in global businesses and has successfully negotiated more than 20 strategic partnership agreements. He was most recently CFO at WCCT Global where he developed the strategic plan, successfully positioning the contract research organization for growth and investment.  Prior to this he was Senior Vice President of Commercial and Corporate Development and CFO of the Late Phase Clinical Group at inVentiv Health. Additionally Peters spent 15 years at ICON Clinical Research where he held the positions of Senior Vice President of Global Finance, Vice President of Finance North and South America, and Controller.

"BioClinica is a dynamic and fast-growing company and I look forward to contributing to its exceptional future," said Peters. Peters, a certified public accountant, earned a Bachelor of Science degree in accounting and information systems from Johnson & Wales University and completed post-graduate studies in business administration at Philadelphia University.

Peters replaces Executive Vice President and CFO Ted Kaminer, who is retiring after 12 years with the company. "A key member of our senior management team, Ted has made significant contributions to the success and substantial growth of our organization," Dr. Hubbard said. "Thanks to the efforts of Ted and his teams, we are well-positioned for the future." Kaminer will stay on with BioClinica during the transition through the end of July.

Follow BioClinica on the Trial Blazers blog at http://www.bioclinica.com/blog, and on Twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.

BioClinica is a specialty clinical trials services provider that improves the development of new medical therapies by delivering expertise and technologies that enhance clinical research data and analytics, worldwide. The company offers industry-leading medical imaging services, enterprise eClinical technologies, clinical research centers and cardiovascular safety solutions that bring quality and efficiency to every phase of clinical development. BioClinica's experience spans three decades and includes thousands of studies in all therapeutic areas. The company serves more than 400 pharmaceutical, biotechnology, and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia. For more information, please visit www.bioclinica.com.

Logo - http://photos.prnewswire.com/prnh/20130403/PH87647LOGO

SOURCE BioClinica, Inc.

Related Links

http://www.bioclinica.com